Description

Canvuparatide, also known as MBX 2109, is a synthetic prodrug of a parathyroid hormone (PTH) peptide. Upon activation, it releases the bioactive PTH[1-32] fragment, which plays a key role in calcium and phosphate regulation in the body. Unlike traditional PTH analogs, Canvuparatide is engineered with a fatty acylated lysine (Lys33) modification at the C-terminal end, which significantly enhances its half-life by improving stability and circulation time.

This extended duration of action makes Canvuparatide an attractive candidate for research in hypoparathyroidism, a condition characterized by low levels of circulating parathyroid hormone. Such deficiency results in hypocalcemia, hyperphosphatemia, neuromuscular irritability, and various skeletal abnormalities. By mimicking the natural activity of PTH, Canvuparatide helps researchers explore mechanisms of calcium homeostasis and potential therapeutic interventions.

With a purity of 95.26% and manufactured under GMP standards, Canvuparatide is suitable for advanced laboratory studies requiring high-quality peptide reagents. Its stability and well-defined mechanism make it a reliable model compound for both academic and pharmaceutical research. Importantly, the compound is available for both wholesale and retail supply, making it accessible to a wide range of laboratories.

Product Specifications

Mechanism of Action & Research Applications

Canvuparatide functions as a prodrug, meaning it is metabolized into its active form once administered. Its primary metabolite is PTH[1-32], which interacts with parathyroid hormone receptors (PTH1R) in bone and kidney tissues. Through receptor activation, it promotes calcium release from bone, enhances renal calcium reabsorption, and regulates phosphate excretion.

The key innovation of Canvuparatide lies in its Lys33 fatty acylation, which extends half-life and reduces dosing frequency. This allows for more stable receptor engagement compared to unmodified PTH fragments.

Research applications include:

• Hypoparathyroidism models: Studying calcium-phosphate imbalances caused by insufficient PTH.

• Bone metabolism studies: Evaluating bone turnover, density, and remodeling in preclinical research.

• Endocrine regulation: Investigating hormonal pathways and feedback mechanisms controlling calcium balance.

• Pharmaceutical development: Exploring prodrug strategies that improve peptide drug stability and duration.

• Comparative studies: Benchmarking against existing PTH analogs to assess relative potency and pharmacokinetics.

These applications highlight Canvuparatide as a valuable compound for peptide drug design research, metabolic disease modeling, and endocrine system exploration.

Side Effects (For Reference in Models)

In experimental and preclinical models, PTH analogs such as Canvuparatide may show potential side effects related to calcium metabolism. These may include:

• Hypercalcemia (elevated calcium levels in the bloodstream)

• Hypercalciuria (increased calcium excretion in urine)

• Phosphate imbalance (due to altered renal handling of phosphate)

• Skeletal effects such as bone remodeling abnormalities with prolonged exposure

• Cardiovascular implications linked to abnormal calcium signaling

These observations are reported in controlled studies and animal models. Actual safety and tolerability must be evaluated in further research. This information is for reference only in models and does not imply any approved clinical usage.

Disclaimer

Canvuparatide (MBX 2109) is provided strictly for laboratory research use only. It is not intended for human or veterinary use, drug development, or household application. Researchers must handle the compound under appropriate laboratory conditions following institutional safety protocols.

Keywords

Canvuparatide, MBX 2109, Canvuparatide peptide, CAS 2925554-87-4, parathyroid hormone prodrug, PTH analog research, hypoparathyroidism research peptide, calcium-phosphate regulation, GMP peptide supplier, peptide wholesale and retail